Tango Therapeutics Inc (TNGX) has a current Price-to-Book (P/B) ratio of 6.23. Compared to its 3-year average P/B ratio of 3.16, the current P/B ratio is approximately 97.13% higher. Relative to its 5-year average P/B ratio of 2.36, the current P/B ratio is about 164.01% higher. Tango Therapeutics Inc (TNGX) has a Forward Free Cash Flow (FCF) yield of approximately -12.20%. Compared to its 3-year average FCF yield of -26.89%, the current FCF yield is approximately -54.62% lower. Relative to its 5-year average FCF yield of -22.17%, the current FCF yield is about -44.95% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TNGX competitors is 368.78, providing a benchmark for relative valuation. Tango Therapeutics Inc Corp (TNGX.O) exhibits a P/S ratio of 2163.07, which is 486.55% above the industry average. Given its robust revenue growth of 363.61%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TNGX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TNGX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TNGX currently overvalued or undervalued?

What is Tango Therapeutics Inc (TNGX) fair value?

TNGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Tango Therapeutics Inc (TNGX) is between to according to relative valuation method.

How does TNGX's valuation metrics compare to the industry average?

The average P/S ratio for TNGX's competitors is 368.78, providing a benchmark for relative valuation. Tango Therapeutics Inc Corp (TNGX) exhibits a P/S ratio of 2163.07, which is 486.55% above the industry average. Given its robust revenue growth of 363.61%, this premium appears sustainable.

What is the current P/B ratio for Tango Therapeutics Inc (TNGX) as of Mar 02 2026?

As of Mar 02 2026, Tango Therapeutics Inc (TNGX) has a P/B ratio of 6.23. This indicates that the market values TNGX at 6.23 times its book value.

What is the current FCF Yield for Tango Therapeutics Inc (TNGX) as of Mar 02 2026?

As of Mar 02 2026, Tango Therapeutics Inc (TNGX) has a FCF Yield of -12.20%. This means that for every dollar of Tango Therapeutics Inc's market capitalization, the company generates -12.20 cents in free cash flow.

What is the current Forward P/E ratio for Tango Therapeutics Inc (TNGX) as of Mar 02 2026?

As of Mar 02 2026, Tango Therapeutics Inc (TNGX) has a Forward P/E ratio of -7.00. This means the market is willing to pay $-7.00 for every dollar of Tango Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Tango Therapeutics Inc (TNGX) as of Mar 02 2026?

As of Mar 02 2026, Tango Therapeutics Inc (TNGX) has a Forward P/S ratio of 2163.07. This means the market is valuing TNGX at $2163.07 for every dollar of expected revenue over the next 12 months.

TNGX Valuation